| Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. | |
| | |
MedLine Citation:
|
PMID: 20380565 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: We examined specific causes of mortality in human immunodeficiency virus type 1 (HIV-1)-infected patients who initiated antiretroviral therapy (ART) in Europe and North America from 1996 through 2006, and we quantified associations of prognostic factors with cause-specific mortality. METHODS: We retrospectively classified all deaths among 39,272 patients enrolled in 13 HIV-1 cohorts (154,667 person years of follow-up) into the categories specified in the Cause of Death (CoDe) project protocol. RESULTS: In 1597 (85%) of 1876 deaths, a definitive cause of death could be assigned. Among these, 792 deaths (49.5%) were AIDS related, followed by non-AIDS malignancies (189; 11.8%), non-AIDS infections (131; 8.2%), violence- and/or drug-related causes (124; 7.7%), liver disease (113; 7.0%), and cardiovascular disease (103; 6.5%). Rates of AIDS-related death (hazard ratio [HR] per 100 cell decrease, 1.43; 95% confidence interval [CI], 1.34-1.53) and death from renal failure (HR, 1.73; 95% CI, 1.18-2.55) were strongly inversely related to CD4 count at initiation of ART, whereas rates of death attributable to AIDS (HR for viral load >5 vs 5 log copies/mL, 1.31; 95% CI, 1.12-1.53), infection (HR, 1.85; 95% CI, 1.25-2.73), cardiovascular (HR, 1.54; 95% CI, 1.05-2.27), and respiratory causes (HR, 3.62; 95% CI, 1.30-10.09) were higher in patients with baseline viral load >5 log copies/mL than in other patients. Rates of each cause of death were higher in patients with presumed transmission via injection drug use than in other patients, with marked increases in rates of liver-related (HR for injection drug use vs non-injection drug use, 6.06; 95% CI, 4.03-9.09) and respiratory tract-related (HR, 4.94; 95% CI, 1.96-12.45) mortality. The proportion of deaths classified as AIDS related decreased with increasing duration of ART. CONCLUSIONS: Important contributors to non-AIDS mortality in treated HIV-1-infected individuals must be addressed if decreases in mortality rates are to continue. |
| | |
Authors:
|
|
Related Documents
:
|
10235515 - Declining hiv/aids mortality in new york city. 15385235 - Costs attributable to aids at household level in chad. 12030215 - Special coverage: 9th conference on retroviruses. tb, pneumonia deaths down, but heart ... 1480685 - Existential anxiety as related to conceptualization of self and of death, denial of dea... 14632435 - Solving the 3-sat problem based on dna computing. 19762585 - Disseminated histoplasmosis in an aids patient: a rare case from southern india. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Volume: 50 ISSN: 1537-6591 ISO Abbreviation: Clin. Infect. Dis. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-19 Completed Date: 2010-07-09 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 9203213 Medline TA: Clin Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 1387-96 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Anti-HIV Agents / therapeutic use* Antiretroviral Therapy, Highly Active* Cause of Death Cohort Studies Europe Female HIV Infections / drug therapy*, mortality*, virology HIV-1 / isolation & purification* Humans Male Middle Aged North America Prognosis Retrospective Studies Risk Factors Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
G0600599//Medical Research Council; U10 AA013566-09/AA/NIAAA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents |
| Investigator | |
Investigator/Affiliation:
|
John Gill / ; Margaret May / ; Charlotte Lewden / ; Mike Saag / ; Michael Mugavero / ; Peter Reiss / ; Bruno Ledergerber / ; Amanda Mocroft / ; Ross Harris / ; Christoph A Fux / ; Amy Justice / ; Dominique Costagliola / ; Jordi Casabona / ; Robert S Hogg / ; Pavel Khaykin / ; Fiona Lampe / ; Janne Vehreschild / ; Jonathan A C Sterne / ; John Gill / ; Charlotte Lewden / ; Mike Saag / ; Matthias Egger / ; Michael Mugavero / ; Peter Reiss / ; Bruno Ledergerber / ; Amanda Mocroft / ; Ross Harris / ; Margaret May / ; Jonathan A C Sterne / ; Hans-Reinhard Brodt / ; Jordi Casabona / ; Genevieve Chene / ; Dominique Costagliola / ; Francois Dabis / ; Antonella D'Arminio Monforte / ; Frank de Wolf / ; Matthias Egger / ; Gerd Fatkenheuer / ; John Gill / ; Jodie Guest / ; Robert S Hogg / ; Amy Justice / ; Ole Kirk / ; Mari Kitahata / ; Fiona Lampe / ; Bruno Ledergerber / ; Peter Reiss / ; Michael Saag / ; Tim Sterling / ; Margaret May / ; Ross Harris / ; Jonathan Sterne / |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receivi...
Next Document: Mixed infections of pandemic H1N1 and seasonal H3N2 viruses in 1 outbreak.